Results 191 to 200 of about 342,042 (343)

Assessment of ethnic differences in pharmacokinetics and clinical responses of acalabrutinib between Chinese and White patients with B‐cell malignancies

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims The aim of this study was to assess differences between Chinese and White patients in pharmacokinetics (PK) of, and clinical response to, acalabrutinib and its pharmacologically active major metabolite, ACP‐5862, to support recommended dosing in Chinese patients with B‐cell malignancies.
Tingting Yao   +5 more
wiley   +1 more source

Oral paltusotine, a nonpeptide selective somatostatin receptor 2 agonist: Mass balance, absolute bioavailability and metabolism in healthy participants

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Paltusotine is a novel, nonpeptide, selective somatostatin receptor 2 agonist in development for the treatment of acromegaly and carcinoid syndrome. This study investigated the mass balance, routes of excretion, absolute bioavailability and metabolite profile of orally administered paltusotine.
Rosa Luo   +6 more
wiley   +1 more source

Use of lipid‐lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2‐year results from Getting to an imprOved Understanding of Low‐Density lipoprotein cholesterol and dyslipidemia management (GOULD)

open access: yesClinical Cardiology, Volume 45, Issue 12, Page 1303-1310, December 2022., 2022
Abstract Background Chronic kidney disease (CKD) is a known risk factor of atherosclerotic cardiovascular disease (ASCVD). Per the 2018 American Heart Association/American College of Cardiology cholesterol guidelines, high‐risk ASCVD patients with CKD and low‐density lipoprotein cholesterol (LDL‐C) levels ≥ $\ge $ 70 mg/dL should take a high‐intensity ...
Aleesha Shaik   +10 more
wiley   +1 more source

Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim TAS5315 is a Bruton tyrosine kinase (Btk) inhibitor in development for autoimmune and allergic diseases, including rheumatoid arthritis (RA) and chronic spontaneous urticaria (CSU). Two clinical studies evaluated the pharmacology and safety of single and multiple oral doses of TAS5315.
Yuji Kumagai   +4 more
wiley   +1 more source

Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a “CASPAR like” outcome from VOYAGER PAD

open access: yesClinical Cardiology, Volume 45, Issue 12, Page 1143-1146, December 2022., 2022
Abstract Background The Clopidogrel and Acetylsalicylic Acid in Bypass Surgery for Peripheral Arterial Disease (CASPAR) trial is the only large, double‐blind, placebo‐controlled trial of dual antiplatelet therapy (DAPT) versus aspirin in patients with peripheral artery disease (PAD) after lower extremity revascularization (LER).
Marc P. Bonaca   +9 more
wiley   +1 more source

Safety of sulfamethoxazole–trimethoprim for the treatment of bacterial infection in outpatient settings: A systematic review and meta‐analysis with active comparator disproportionality analysis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Sulfamethoxazole–trimethoprim (SMX‐TMP) is a widely used antibiotic for treating bacterial infections, but its safety in adult outpatients remains understudied. This systematic review and meta‐analysis evaluated the safety profile of SMX‐TMP and identified critical research gaps.
Rebecca Preyra   +4 more
wiley   +1 more source

EudraVigilance insights: Suspected adverse drug reactions in infants through breastfeeding

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims We aimed to describe suspected adverse drug reactions (ADRs) in infants resulting from medications transmitted through mothers' milk, as reported to the European ADR database, EudraVigilance. The research sought to understand the frequency, seriousness and nature of these ADRs to assess potential risks associated with maternal medication use ...
Ida M. Heerfordt   +7 more
wiley   +1 more source

Treatment‐related adverse events of antibody–drug conjugates in clinical trials: A systematic review and meta‐analysis

open access: yesCancer, Volume 129, Issue 2, Page 283-295, 15 January 2023., 2023
Abstract Background Antibody–drug conjugates (ADCs) have complex molecular structures and have been tested in numerous clinical trials. Therefore, understanding the mechanisms of their toxicity when applied in medical practice is of high importance. Methods In a systematic review and meta‐analysis of data gathered from different scientific databases ...
Youwen Zhu   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy